J&J Medical Connect
Neuroscience
Neuroscience

Congress Materials – European College of Neuropsychopharmacology (ECNP 2026)

 

2026 European College of Neuropsychopharmacology | Oct 10-13 | Munich, Germany

This section includes selected Johnson & Johnson Innovative Medicine abstracts, posters, or oral presentations, which have been accepted for congress presentations in the last 2 years or less (as determined by any congress restrictions on length of time materials can be posted). Information about pipeline products or investigational uses of products does not imply FDA approval for these products or uses, nor does it establish the safety or efficacy of these products or uses. Johnson & Johnson does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling. The content contained in this section is subject to congress copyright permissions.

Adjunctive Lumateperone 42 mg Treatment in Major Depressive Disorder: Efficacy Across Patient-Reported Depression Symptoms

Rakesh Jain, Suresh Durgam, Willie R. Earley, Susan G. Kozauer, Maxine Chen, Changzheng Chen


This document will be available on Oct 11th 2026

Assessment of Lumateperone Partial Agonist Activity at Presynaptic Dopamine D2 Autoreceptors: Reversal of Haloperidol-Induced Tyrosine Hydroxylase Phosphorylation in Mouse Striatum

Maxine Chen, Sophie Dutheil, Gretchen L. Snyder


This document will be available on Oct 10th 2026

Cardiometabolic Risk After Antidepressant and Antipsychotic Treatment in Major Depressive Disorder: Evidence From German Health Claims Data

Nilanjana Dwibedi, Jing Zhao, Mohammed Dagher, M. Janelle Cambron-Mellott, Roman Kliemt, Nils Kossack, Marc Pignot


This document will be available on Oct 10th 2026

Changes in depression severity and functionality after 5-month treatment with esketamine nasal spray in a Spanish real-world population: Interim analysis of the HIPOCRAT-ESK study

Ángela Ibañez Cuadrado, Narcís Cardoner Álvarez, Enrique Baca Garcia, Sergio Benavente Lopez, Jose Manuel Crespo Iglesias, Luis Gutierrez Rojas, Diego José Palao Vidal, Marta García Dorado, Patricia Hinojar Merín


This document will be available on Oct 10th 2026

Double-Blind and Open-Label Extension Results From a Phase-3 Trial of Adjunctive Seltorexant in Adults With Major Depressive Disorder With Insomnia Symptoms

Gahan Pandina, Michael E. Thase, Andrew D. Krystal, Ewa Wajs, Joseph M. Trombello, Ryan Kelly, Yun Zhang, Haiyan Xu, John Thipphawong, Sandra Ruschel, Yanina Flossbach, Carla M. Canuso, Thomas Laughren, Wayne C. Drevets


This document will be available on Oct 13th 2026

Efficacy of Adjunctive Lumateperone 42 mg Treatment Across a Broad Range of Depression Symptoms in Patients With Major Depressive Disorder

Christoph U. Correll, Suresh Durgam, Willie R. Earley, Ibrahim Turkoz, John J. Sheehan, Roger S. McIntyre


This document will be available on Oct 10th 2026

Impact of Seltorexant on Cognitive Performance of Adults With Major Depressive Disorder With Insomnia Symptoms

Amy Wegener, Ryan Kelly, Yun Zhang, Randall L. Morrison, Yanina Flossbach, Sofie Mesens, Wayne C. Drevets, Gahan Pandina


This document will be available on Oct 10th 2026

Linking Montgomery-Asberg Depression Rating Scale and Patient Health Questionnaire Total Scores: Evidence from Adjunctive Lumateperone Trial Data

Taeho Greg Rhee, Suresh Durgam, Willie R. Earley, Ibrahim Turkoz, John J. Sheehan


This document will be available on Oct 10th 2026

Lumateperone 42 mg in Major Depressive Disorder: Demographic and Clinical Subgroups Efficacy Analysis in a Phase 3 Randomized Placebo-Controlled Trial

Raffaele Migliore, Suresh Durgam, Willie R. Earley, Yifan Mo, Hassan Lakkis, Susan G. Kornstein


This document will be available on Oct 10th 2026

Lumateperone 42 mg in Patients With Major Depressive Disorder: Analysis of Remission in Short- and Long-Term Trials

Michael E. Thase, Willie R. Earley, Changzheng Chen, Tobie Escher, Suresh Durgam


This document will be available on Oct 10th 2026

Metabolic Profile of Adjunctive Lumateperone 42 mg in Major Depressive Disorder: A Pooled Analysis of 2 Randomized, Placebo-Controlled Trials

Metabolic Profile of Adjunctive Lumateperone 42 mg in Major Depressive Disorder: A Pooled Analysis of 2 Randomized, Placebo-Controlled Trials


This document will be available on Oct 10th 2026

Predictors of Response With Adjunctive Lumateperone in Patients With Major Depressive Disorder: A Pooled Analysis of 2 Phase 3 Trials

Manpreet K. Singh, Suresh Durgam, Willie R. Earley, Andrea C. Wilson, John J. Sheehan, Ibrahim Turkoz


This document will be available on Oct 11th 2026

Real-World Effectiveness and Treatment Duration by Psychiatric Comorbidity Status: Esketamine Nasal Spray for Treatment-Resistant Depression

Vassilis Martiadis, Bernhard T. Baune, Kfir Feffer, Yerkebulan Kambarov, Stephan Köhler, José Manuel Olivares, Ibrahim Turkoz, Christian von Holt, Gianluca Rosso


This document will be available on Oct 12th 2026

Real-World Effectiveness of Esketamine Nasal Spray in Treatment Resistant Depression: Results From the ECHO Prospective Non-Interventional Cohort Study

Stephan Köhler, Jordan Godinov, Lars Häggström, Angela Ibañez, Vassilis Martiadis, Christine Reif-Leonhard, Jesper Riise, Gianluca Rosso, Ibrahim Turkoz, Bernhard T. Baune


This document will be available on Oct 11th 2026

Real-World Outcomes of Esketamine in Major Depressive Disorder With Comorbid Anxiety or Trauma and Stress-Related Disorders (ELLIPSE Study)

PM. Llorca, P. de Maricourt, L. Mekaoui, M. Rothärmel, I. Rodriguez, H. Lacour, B. Grenier, M. Mabred, , J. Dupin, , C. Wicart


This document will be available on Oct 10th 2026

Real-World Post-Treatment Durability of Esketamine Nasal Spray Effectiveness in Treatment Resistant Depression: Results from the ECHO Non-Interventional Cohort Study

Christine Reif-Leonhard, Sergio De Filippis, Jordan Godinov, Angela Ibañez, Tetsuro Ito, Etienne Olivier, Maria Pepe, Tamara Werner-Kiechle, Dieter Zeeuws, Eric Constant


This document will be available on Oct 11th 2026

Real‑World Esketamine Nasal Spray Treatment Duration and Dosing in Patients With Treatment‑Resistant Depression: Findings From ECHO, a Non‑Interventional Study

Eric Constant, Kfir Feffer, Christian von Holt, José Manuel Olivares, Maria Pepe, Maurizio Pompili, Kamran Shafieian, Tamara Werner-Kiechle, Dieter Zeeuws, Lars Häggström


This document will be available on Oct 13th 2026

 

Copies of these presentations are for personal use only and may not be reproduced without written permission from the presentation author.

J&J Medical Connect

Connect with us

Connect with us

Would you like to clear and leave your conversation? Message history will be lost.